Kite Pharma Appoints Chris Nowers as Head of Europe to Lead Commercial Operations & Advance the Company’s CAR/TCR Therapy P...
October 13 2016 - 7:30AM
Business Wire
Kite Pharma, Inc. (Nasdaq:KITE) today announced the appointment
of Chris Nowers as its Head of Europe. Nowers will be based in
London. In his new role, Nowers will oversee European
commercial operations to build awareness in the region
of Kite’s growing pipeline portfolio of chimeric
antigen receptor (CAR) and T-cell receptor (TCR) therapy product
candidates and prepare for the potential launch of the
company’s lead product candidate, KTE-C19.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161013005478/en/
Chris Nowers, Head of Europe, Kite Pharma
(Photo: Business Wire)
“The addition of Chris Nowers to our executive team will be
instrumental to Kite as we expand our global footprint,” said Arie
Belldegrun, M.D., FACS, Chairman, President and Chief Executive
Officer of Kite. “The breadth of Chris’ commercial experience in
global immuno-oncology is impressive, and makes him well-qualified
to propel our pipeline of CAR-T and TCR therapy candidates to treat
both blood-based and solid cancers into international markets.”
A seasoned executive with 30 years of commercial leadership
experience in pharmaceutical, biotech and diagnostics companies,
Nowers brings a track record of successfully driving differentiated
strategies for product commercialization across therapeutic areas
in a competitive global landscape.
“Kite is a truly innovative company at the cusp of transforming
the paradigm of cancer treatment, and I am honored to play a role
in bringing what could potentially be life-changing therapies to
patients around the world,” said Nowers. “I look forward to working
with such a dynamic and passionate team to advance our presence in
Europe and continue our efforts in developing novel approaches in
engineered cell therapy.”
Prior to joining Kite, Nowers held senior commercial leadership
positions at Bristol-Myers Squibb, including Head of
Immuno-oncology and Hematology in France, where he led the
successful launch of Opdivo (nivolumab), and as Vice President of
Global Commercialization for Yervoy (ipilimumab), where he led the
global commercial launch. Previously, Nowers was Vice President of
Sales and Marketing at Genomic Health, Inc., and Chief Executive
Officer of Avantogen Oncology Inc., a company developing
early-stage cancer therapeutics. Nowers also served 11 years at
Amgen Inc. in a variety of commercial leadership roles, including
Global Commercial Leader for Neurology and European Director for
Oncology and Hematology.
About KTE-C19
Kite Pharma’s lead product candidate, KTE-C19, is an
investigational therapy in which a patient’s T cells are engineered
to express a CAR to target the antigen CD19, a protein expressed on
the cell surface of B-cell lymphomas and leukemias, and redirect
the T cells to kill cancer cells. KTE-C19 has been granted
Breakthrough Therapy Designation status for diffuse large B-cell
lymphoma (DLBCL), transformed follicular lymphoma (TFL), and
primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food
and Drug Administration and Priority Medicines (PRIME) regulatory
support for DLBCL in the EU.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company
engaged in the development of novel cancer immunotherapy products,
with a primary focus on engineered autologous cell therapy (eACT™)
designed to restore the immune system’s ability to recognize and
eradicate tumors. Kite is based in Santa Monica, CA. For
more information on Kite Pharma, please
visit www.kitepharma.com. Sign up to follow @KitePharma on
Twitter at www.twitter.com/kitepharma.
Kite Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the ability to expand European operations, and
obtain approval for and commercially launch KTE-C19 and additional
product candidates internationally. Various factors may cause
differences between Kite’s expectations and actual results as
discussed in greater detail in Kite’s filings with the Securities
and Exchange Commission, including without limitation in its Form
10-Q for the quarter ended June 30, 2016. Any forward-looking
statements that are made in this press release speak only as of the
date of this press release. Kite assumes no obligation to update
the forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161013005478/en/
Kite Pharma, Inc.Christine CassianoSVP, Corporate
Communications & Investor
Relationsccassiano@kitepharma.comorGreg MannVP, Investor
Relationsgmann@kitepharma.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Apr 2024 to May 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From May 2023 to May 2024